Carisma Therapeutics (CARM) Institutional Ownership $0.87 +0.01 (+0.83%) (As of 09:15 AM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Carisma Therapeutics (NASDAQ:CARM)CurrentInstitutional OwnershipPercentage44.27%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.20MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$2.62M Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CARM Institutional Buying and Selling by Quarter Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Carisma Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/16/2024 Geode Capital Management LLC259,184$254K0.0%-8.5%0.621% 11/15/2024 Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/15/2024 Wexford Capital LP34,861$34K0.0%+75.5%0.083% 9/16/2024 Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024 Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024 TPG GP A LLC842,031$1.28M0.0%-42.0%2.027% 8/9/2024 Renaissance Technologies LLC139,360$212K0.0%-38.3%0.335% 5/10/2024 Vanguard Group Inc.1,579,961$3.59M0.0%+0.7%3.803% 5/7/2024 Empowered Funds LLC26,984$61K0.0%-43.9%0.065% 2/14/2024 Trustees of The University of Pennsylvania1,252,107$3.67M10.3%-28.9%3.102% 10/13/2023 SG Americas Securities LLC13,653$58K0.0%N/A0.034% 9/21/2023 Barclays PLC5,312$47K0.0%N/A0.013% 8/4/2023 American International Group Inc.12,834$113K0.0%N/A0.032% 7/27/2023EA Series Trust40,434$355K0.0%N/A0.100% 6/15/2023 Trustees of The University of Pennsylvania2,182,812$6.77M6.6%N/A5.422% 5/15/2023 Wittenberg Investment Management Inc.46,703$145K0.1%N/A0.459% 5/12/2023 Deuterium Capital Management LLC51,256$159K0.2%N/A0.504% 5/10/2023 Connor Clark & Lunn Investment Management Ltd.14,796$46K0.0%N/A0.145% 5/3/2023 Jump Financial LLC17,542$54K0.0%N/A0.172% 5/1/2023Virtu Financial LLC15,335$48K0.0%N/A0.151% 4/27/2023Stratos Wealth Partners LTD.19,899$62K0.0%N/A0.195% 4/24/2023 Blodgett Wealth Advisors LLC29,660$92K0.1%N/A0.291% 4/14/2023 BML Capital Management LLC411,398$1.28M1.1%N/A4.041% (Data available from 1/1/2016 forward) CARM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CARM shares? During the previous two years, 20 institutional investors and hedge funds held shares of Carisma Therapeutics. The most heavily invested institutionals were Trustees of The University of Pennsylvania ($3.67M), Vanguard Group Inc. ($3.59M), TPG GP A LLC ($1.28M), BML Capital Management LLC ($1.28M), Barclays PLC ($539K), EA Series Trust ($355K), and Geode Capital Management LLC ($254K).Learn more on CARM's institutional investors. What percentage of Carisma Therapeutics stock is owned by institutional investors? 44.27% of Carisma Therapeutics stock is owned by institutional investors. Learn more on CARM's institutional investor holdings. Which institutional investors have been buying Carisma Therapeutics stock? Of the 16 institutional investors that purchased Carisma Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Trustees of The University of Pennsylvania ($2.18M), Barclays PLC ($1.10M), BML Capital Management LLC ($411.40K), Point72 Asia Singapore Pte. Ltd. ($52.01K), Deuterium Capital Management LLC ($51.26K), Wittenberg Investment Management Inc. ($46.70K), and EA Series Trust ($40.43K). How much institutional buying is happening at Carisma Therapeutics? Institutional investors have bought a total of 4,038,426 shares in the last 24 months. This purchase volume represents approximately $10.42M in transactions. Which Carisma Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Carisma Therapeutics stock in the last 24 months: TPG GP A LLC ($609.85K), Trustees of The University of Pennsylvania ($507.74K), Renaissance Technologies LLC ($86.64K), Geode Capital Management LLC ($24.22K), and Empowered Funds LLC ($21.15K). How much institutional selling is happening at Carisma Therapeutics? Institutional investors have sold a total of 1,249,596 shares in the last 24 months. This volume of shares sold represents approximately $2.62M in transactions. Related Companies Cytosorbents Major Shareholders TherapeuticsMD Major Shareholders Sensei Biotherapeutics Major Shareholders Aspira Women's Health Major Shareholders Exagen Major Shareholders Black Diamond Therapeutics Major Shareholders Inventiva Major Shareholders Acumen Pharmaceuticals Major Shareholders Elutia Major Shareholders FitLife Brands Major Shareholders This page (NASDAQ:CARM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
